
Human G2/mitotic-specific cyclin-B1 204-212, ILIDWLVQV
Description
About Human G2/mitotic-specific cyclin-B1 204-212, ILIDWLVQV
The Human G2/mitotic-specific cyclin-B1 Peptide (IEDB: 466581) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The G2/mitotic-specific cyclin-B1 Peptide, H-ILIDWLVQV-OH (Uniprot: P14635 aa: 204-212) from JPT is produced under strict quality control and quality management.
Human G2/mitotic-specific cyclin-B1 204-212, ILIDWLVQV - Specifications
- Peptide sequence: H-ILIDWLVQV-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Melanoma
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human G2/mitotic-specific cyclin-B1 204-212, ILIDWLVQV
References:
Read References with JPT’s Antigen Peptides
Human G2/mitotic-specific cyclin-B1 204-212, ILIDWLVQV has been described in:
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade., Front Immunol, 2022 (PMID: 35874702)
The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference., J Immunol, 2016 (PMID: 26783342)
Documentation
Documentation for Human G2/mitotic-specific cyclin-B1 204-212, ILIDWLVQV
Properties
Properties of Human G2/mitotic-specific cyclin-B1 204-212, ILIDWLVQV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Melanoma |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | G2/mitotic-specific cyclin-B1 |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human G2/mitotic-specific cyclin-B1 204-212, ILIDWLVQV
Information | Values |
---|---|
Sequence: | H-ILIDWLVQV-OH |
Specifications: | 9mer peptide as TFA salt |